Economic outcomes: Cost of care · people with psychosis‐induced aggression
1 finding from 1 review
Tranquil or asleep: Not tranquil or asleep ‐ by 30 mins · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in tranquil or asleep: Not tranquil or asleep ‐ by 30 mins compared with ANTIPSYCHOTIC ‐ OLANZAPINE (high certainty).
1 finding from 1 review
Global state: Needing restraints or seclusion ‐ by 12 hours · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in global state: Needing restraints or seclusion by 12 hours compared with ANTIPSYCHOTIC ‐ OLANZAPINE (low certainty).
1 finding from 1 review
Mental state: No 20% response (as defined by PANSS/BPRS total change) · patients with schizophrenia
It is very uncertain whether RISPERIDONE changes mental state: no clinically significant response in psychotic… compared with PLACEBO (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
RISPERIDONE may leads to lower leaving the study early ‐ short term (up to 12 weeks) ‐ any reason compared with PLACEBO (low certainty).
1 finding from 1 review
Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks) · patients with schizophrenia
It is very uncertain whether RISPERIDONE changes global state: 2. no significant clinical improvement ‐ CGI, short… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS · patients with schizophrenia
RISPERIDONE may leads to higher adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term… compared with PLACEBO (low certainty).
1 finding from 1 review
Mental state: No 20% response (as defined by PANSS/BPRS total change) · patients with schizophrenia
RISPERIDONE + CLOZAPINE showed no clear difference in mental state: no clinically significant response in psychotic… compared with PLACEBO + CLOZAPINE (low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks) · patients with schizophrenia
RISPERIDONE + CLOZAPINE showed no clear difference in global state: no significant clinical improvement ‐ CGI short term compared with PLACEBO + CLOZAPINE (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · people with psychosis
1 finding from 1 review
no estimate extracted
1 study · 5 participants
Very low
Global state: No clinically significant response (as defined by the original studies) · people with psychosis
1 finding from 1 review
General functioning: improved to an important degree · people with psychosis
2 findings from 1 review
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with psychosis
1 finding from 1 review
Quality of life: improved to an important degree · people with psychosis
3 findings from 1 review
no estimate extracted
0 studies · 0 participants
GRADE not reported
no estimate extracted
0 studies · 0 participants
GRADE not reported
no estimate extracted
0 studies · 0 participants
GRADE not reported
Mental state · people with psychosis
2 findings from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · people with psychosis
2 findings from 1 review
Global state: general ‐no clinically significant improvement ‐ data only for mifepristone < 30% improvement on BPRS · people with psychosis
It is very uncertain whether any antiglucocorticoid changes global state: general ‐no clinically significant improvement ‐ data… compared with placebo (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · people with psychosis
1 finding from 1 review